Another quarter, another cull for Moderna. The company snuck into its second-quarter earnings report (PDF) that development of an mRNA treatment for IL-2-based autoimmune disorders has ended. Moderna ...

Results from Phase 1a portion of trial show first-in-class α/β biased IL-2 has potential to decouple efficacy and toxicity of IL-2 First dose expansion cohorts in Phase 1b portion of trial will ...

Werewolf Therapeutics is developing a "conditionally activated" interleukin-2 (IL-2) drug for the treatment of stage IV melanoma and metastatic cancers. The drug aims to deliver therapeutic doses of ...

Interleukin-2 (IL-2) is a cytokine, a type of immune system signaling molecule, that plays a crucial role in the body's response to microbial infections and in distinguishing between self and non-self ...

The writing is on the wall at Mural Oncology. Responding to clinical data, the biotech is laying off 90% of its employees and stopping clinical development of its lead program to hunker down and seek ...

Oleg Maddox’s world famous IL-2 Sturmovik series of flight simulators continues to expand. The latest offering, IL-2 1946, adds 36 new planes, four new gigantic maps, over a hundred new ground objects ...